Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3968621 first-in-human dose-escalation study alone and with ezabenlimab in advanced solid tumors
jRCT2031260586Phase 1Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of BI 3968621 and ezabenlimab in Nonhematologic neoplasms (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities and Objective response. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BI 3968621ezabenlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031260586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260586.